Arrowstreet Capital
LFCR icon

Arrowstreet Capital’s Lifecore Biomedical LFCR Stock Holding History

Arrowstreet Capital’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,014
Closed -$92K – 1592
2021
Q3 		$92K Sell
10,014
-43,269
-81% -$471K ﹤0.01% 1543
2021
Q2 		$599K Sell
53,283
-105,417
-66% -$1.22M ﹤0.01% 1653
2021
Q1 		$1.68M Sell
158,700
-46,158
-23% -$519K ﹤0.01% 1619
2020
Q4 		$2.22M Buy
204,858
+33,383
+19% +$345K ﹤0.01% 1560
2020
Q3 		$1.67M Sell
171,475
-3,904
-2% -$37.2K ﹤0.01% 1635
2020
Q2 		$1.4M Buy
+175,379
New +$1.81M ﹤0.01% 1637
2018
Q4 		– Sell
-26,500
Closed -$382K – 1427
2018
Q3 		$382K Buy
26,500
+15,039
+131% +$208K ﹤0.01% 947
2018
Q2 		$171K Buy
+11,461
New +$159K ﹤0.01% 1014
2017
Q2 		– Sell
-19,921
Closed -$239K – 1208
2017
Q1 		$239K Buy
+19,921
New +$252K ﹤0.01% 1178
2016
Q4 		– Sell
-73,550
Closed -$986K – 2138
2016
Q3 		$986K Sell
73,550
-41,897
-36% -$507K ﹤0.01% 1073
2016
Q2 		$1.24M Sell
115,447
-103,184
-47% -$1.14M ﹤0.01% 962
2016
Q1 		$2.3M Buy
218,631
+30,485
+16% +$335K 0.01% 761
2015
Q4 		$2.23M Sell
188,146
-10,947
-5% -$134K 0.01% 774
2015
Q3 		$2.32M Buy
199,093
+16,400
+9% +$217K 0.01% 711
2015
Q2 		$2.64M Sell
182,693
-3,738
-2% -$53.9K 0.01% 579
2015
Q1 		$2.6M Sell
186,431
-40,326
-18% -$557K 0.02% 548
2014
Q4 		$3.13M Buy
226,757
+59,598
+36% +$770K 0.02% 588
2014
Q3 		$2.05M Buy
167,159
+147,464
+749% +$1.84M 0.01% 582
2014
Q2 		$246K Sell
19,695
-2,983
-13% -$35.1K ﹤0.01% 902
2014
Q1 		$253K Buy
+22,678
New +$249K ﹤0.01% 1060

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Arrowstreet Capital's LFCR Position: Q4 2021 in Review

Arrowstreet Capital sold out of Lifecore Biomedical (LFCR) in Q4 2021, closing a stake of 10,014 shares — an estimated $92K sold.

Arrowstreet Capital first reported a position in LFCR in Q1 2014 and held it in 20 quarters. The position peaked at $3.13M in Q4 2014. 98 funds tracked by Wall St. Rank hold LFCR as of Q4 2021.

  • Arrowstreet Capital reported no remaining Lifecore Biomedical position as of Q4 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 10,014 Lifecore Biomedical shares in Q4 2021, an estimated $92K.
  • Arrowstreet Capital first reported a position in Lifecore Biomedical in Q1 2014 and held it in 20 quarters.
  • Arrowstreet Capital's Lifecore Biomedical position peaked at $3.13M in Q4 2014.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2021.

Based on Arrowstreet Capital's 13F filing for Q4 2021, filed 14 Feb 2022.